Zobrazeno 1 - 10
of 670
pro vyhledávání: '"atezolizumab plus bevacizumab"'
Autor:
Etsuko Moriyama, Shigeo Shimose, Takashi Niizeki, Hideki Iwamoto, Masatoshi Tanaka, Tomotake Shirono, Yu Noda, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 5821-5831 (2024)
This retrospective study aimed to evaluate the impact of atezolizumab plus bevacizumab–transcatheter arterial chemoembolization (TACE) sequential therapy in unresectable hepatocellular carcinoma (HCC), especially in patients with intermediate-stage
Externí odkaz:
https://doaj.org/article/d77367d9de414f0eabdaebb91dca7b40
Autor:
Choong-kun Lee, Changhoon Yoo, Jung Yong Hong, Se Jun Park, Jin Won Kim, David Wai Meng Tai, Hyeyeong Kim, Krittiya Korphaisarn, Suebpong Tanasanvimon, San-Chi Chen, Ju Won Kim, Ilhwan Kim, Moonho Kim, Joan Choo, Sang-Bo Oh, Ching-Tso Chen, Woo Kyun Bae, Hongsik Kim, Seok Jae Huh, Chia-Jui Yen, Sejung Park, Dong Ki Lee, Landon Long Chan, Beodeul Kang, Minsu Kang, Raghav Sundar, Hye Jin Choi, Stephen Lam Chan, Hong Jae Chon, Myung-Ah Lee
Publikováno v:
Liver Cancer, Pp 1-15 (2024)
Introduction: Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared to sorafenib. However, optimal subsequent treatment options for patients w
Externí odkaz:
https://doaj.org/article/48cd992dee674cbb8551afa29b350663
Autor:
Tasuku Nakabori, Sena Higashi, Yutaro Abe, Kaori Mukai, Toshiki Ikawa, Koji Konishi, Noboru Maeda, Katsuyuki Nakanishi, Shinichiro Hasegawa, Hiroshi Wada, Kazuyoshi Ohkawa
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1543-1555 (2024)
Various locoregional treatments for localized hepatocellular carcinoma (HCC) have been developed. This retrospective study investigated the safety and feasibility of combining on-demand selective locoregional treatment for residual lesions after tumo
Externí odkaz:
https://doaj.org/article/72a5cbc348944a46a1564ca2199487be
Autor:
Haidong Ai, Ting Gong, Yongbiao Ma, Guixu Ma, Wei Ding, Weibao Ding, Wenjuan Wang, Xuelin Zhao
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Hepatocellular carcinoma (HCC) ranks as the sixth most common malignancy globally, with the majority of patients presenting at the initial diagnosis with locally advanced or metastatic disease, precluding the opportunity for curative surgical interve
Externí odkaz:
https://doaj.org/article/a253cce4b85b46b5b5fee57baccc1285
Autor:
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Takeshi Hatanaka, Joji Tani, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Kazuto Tajiri, Toru Ishikawa, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Chikara Ogawa, Satoru Kakizaki, Noritomo Shimada, Atsushi Naganuma, Kazuhito Kawata, Hisashi Kosaka, Hidekatsu Kuroda, Tomomitsu Matono, Yutaka Yata, Hironori Ochi, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada, Representing the Real‐life Practice Experts for HCC Study Group with Hepatocellular Carcinoma experts from 48 clinics in Japan (RELPEC/HCC 48 Group)
Publikováno v:
Cancer Reports, Vol 7, Iss 4, Pp n/a-n/a (2024)
Abstract Aims The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods A total o
Externí odkaz:
https://doaj.org/article/db2c34e45940412fa92f5beffa4e949a
Autor:
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Atsushi Naganuma, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Kazunari Tanaka, Takaaki Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21680-21693 (2023)
Abstract Aim This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. Methods We included 526 patients who received Atez/Bev and 731
Externí odkaz:
https://doaj.org/article/47d83858206f4fedb8133cae3683b6fd
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 10, Pp 1195-1206 (2023)
Chenghao Zhao,* Zhanwang Xiang,* Mingan Li, Haofan Wang, Huan Liu, Huzheng Yan, Mingsheng Huang Department of Interventional Radiology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, People’s Republic of China&a
Externí odkaz:
https://doaj.org/article/ca6d62b031d34a21acdb480e882b08fb
Autor:
Takahiro Kinami, Shinsuke Uchikawa, Tomokazu Kawaoka, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kei Amioka, Kensuke Naruto, Kenji Yamaoka, Yasutoshi Fujii, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Masataka Tsuge, Shiro Oka
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Aim Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC). Serious adverse events (AEs), including rupture of esophagogastric varices, have be
Externí odkaz:
https://doaj.org/article/750b5eb5b5f54de5bfbf22b2506451a0
Autor:
Ji Won Han, Pil Soo Sung, Jae-Sung Yoo, Hee Sun Cho, Soon Kyu Lee, Hyun Yang, Ji Hoon Kim, Heechul Nam, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Hyun Kwon, Chang Wook Kim, Si Hyun Bae, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundAtezolizumab+bevacizumab (AB) and lenvatinib have been proposed as first-line treatment options for patients with advanced hepatocellular carcinoma (HCC), but comparative efficacy and associated factors are controversial.Materials and metho
Externí odkaz:
https://doaj.org/article/a5bacfced7d94a80ad9b89efcedec63c
Autor:
Shigeo Shimose, Hideki Iwamoto, Tomotake Shirono, Masatoshi Tanaka, Takashi Niizeki, Masahiko Kajiwara, Satoshi Itano, Yoichi Yano, Satoru Matsugaki, Etsuko Moriyama, Yu Noda, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12325-12335 (2023)
Abstract Background and Aims We aimed to validate the predictive factors for tumor response and the prognostic impact of conversion therapy aimed at cancer‐ and drug‐free states in patients with unresectable hepatocellular carcinoma (u‐HCC) und
Externí odkaz:
https://doaj.org/article/26571559f9b244bc907903ba1baffeb9